Recently, according to the "2023 Comprehensive Report" released by Philip Morris International (PMI), the global user base for its heated tobacco product, IQOS, has grown by 15% in the past year, reaching approximately 28.6 million people. Additionally, sales of PMI's non-combustible products have surpassed its total sales in 25 countries, an increase of 8 countries compared to the previous year.
This report, released for the fifth consecutive year, serves as a milestone in achieving PMI's "Smoke-free Future" vision. By 2023, the number of users of its non-combustible products has exceeded 33 million, with approximately 28.6 million using IQOS, a 15% increase from the previous year's 24.9 million users. Additionally, the number of countries with annual net sales growth exceeding 50% has increased from 17 to 25.
According to statistics, 36.4% of Philip Morris International's (PMI) adjusted net income in 2023 comes from smoke-free products. PMI's smoke-free products are sold in 84 markets worldwide, with 47% of them located in low- and middle-income markets.
In 25 markets, non-smoking products account for over 50% of annual net income. Since 2008, a total of $12.5 billion has been invested in these non-smoking products.
Philip Morris International (PMI) CEO, Jacek Olczak, stated, "2023 is the year of our unity, determination, and the continued efforts towards a 'smoke-free future'. Despite facing new challenges, as long as we have exceptional resilience, capabilities, and a clear sense of purpose, we can lead positive change through innovation and promote sustainability."
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
